Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Advisory

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference


Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New York City.

2024 RBC Capital Markets Global Healthcare Conference

A webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their RBC representative.

About Vistagen

Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen's clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neurocircuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen's sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.


These press releases may also interest you

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
Astera Labs Extends Interoperability Leadership Driving Seamless PCIe 6.x Deployment
Astera Labs , a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced expanded PCIe® 6.x testing capabilities in its Cloud-Scale Interop Lab to enable seamless interoperability between Aries 6...

at 02:05
Exchange Solutions Unveils Industry-First Generative AI Feature Enablement for a Loyalty Platform
Exchange Solutions, a leading provider of personalized loyalty solutions, proudly announces the launch of groundbreaking Generative AI features integrated into its loyalty platform. This innovative advancement, now available for use within the SaaS...

at 02:05
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...

at 02:04
Stay updated, stay connected: Dive into Shanghai with a subscription
A news report from english.shanghai.gov.cn: Are you interested in Shanghai but lack the time or aren't sure where to find information about the city? Look no further. The International Services Shanghai newsletter gives you a hassle-free way to stay...

at 02:00
Tuniu to Report First Quarter 2024 Financial Results on June 4, 2024
Tuniu Corporation ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2024, before the market opens on June 4,...

More news about Science and technology...


News published on and distributed by: